KR20240128059A - 화합물 - Google Patents

화합물 Download PDF

Info

Publication number
KR20240128059A
KR20240128059A KR1020247024904A KR20247024904A KR20240128059A KR 20240128059 A KR20240128059 A KR 20240128059A KR 1020247024904 A KR1020247024904 A KR 1020247024904A KR 20247024904 A KR20247024904 A KR 20247024904A KR 20240128059 A KR20240128059 A KR 20240128059A
Authority
KR
South Korea
Prior art keywords
heterocycloalkyl
cycloalkyl
alkyl
alkynyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247024904A
Other languages
English (en)
Korean (ko)
Inventor
사무엘 배니스터
윌리엄 요르겐센
진룽 탄
Original Assignee
사일로 피티와이 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021904268A external-priority patent/AU2021904268A0/en
Application filed by 사일로 피티와이 엘티디 filed Critical 사일로 피티와이 엘티디
Publication of KR20240128059A publication Critical patent/KR20240128059A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247024904A 2021-12-24 2022-12-23 화합물 Pending KR20240128059A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021904268 2021-12-24
AU2021904268A AU2021904268A0 (en) 2021-12-24 Compounds
PCT/AU2022/051591 WO2023115165A1 (en) 2021-12-24 2022-12-23 Compounds

Publications (1)

Publication Number Publication Date
KR20240128059A true KR20240128059A (ko) 2024-08-23

Family

ID=86900872

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247024904A Pending KR20240128059A (ko) 2021-12-24 2022-12-23 화합물

Country Status (10)

Country Link
US (1) US20250163044A1 (https=)
EP (1) EP4452979A4 (https=)
JP (1) JP2025501141A (https=)
KR (1) KR20240128059A (https=)
CN (1) CN118974044A (https=)
AU (1) AU2022422215A1 (https=)
CA (1) CA3241845A1 (https=)
IL (1) IL313857A (https=)
MX (1) MX2024007911A (https=)
WO (1) WO2023115165A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
WO2021226416A1 (en) 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
EP4255422A4 (en) * 2020-12-03 2024-12-18 Mydecine Innovations Group Inc. NEW PSILOCIN ANALOGUE COMPOSITIONS AND METHODS OF THEIR SYNTHESIS
KR20240058859A (ko) 2021-08-12 2024-05-03 쿨레온 엘엘씨 환각성 및 비환각성 세로토닌 수용체 작용제 및 이의 제조 및 사용 방법
IL313455A (en) 2021-12-15 2024-08-01 Delix Therapeutics Inc Phenoxy and benzyloxy modified psychroplastogens and their uses
WO2023129956A2 (en) 2021-12-30 2023-07-06 ATAI Life Sciences AG Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2025000053A1 (en) * 2023-06-28 2025-01-02 Psylo Pty Ltd Compounds
WO2025000051A1 (en) 2023-06-28 2025-01-02 Psylo Pty Ltd Pyrrolopyridine compounds for the treatment of mental illnesses
WO2026030052A1 (en) 2024-07-31 2026-02-05 Fmc Corporation Fungicidal substituted azoles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977131A (en) * 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
GB9819020D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds III
EP1132389A1 (en) * 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
MXPA04011791A (es) * 2002-05-30 2005-07-26 Jesse A May Piranoindazoles y su uso para el tratamiento de glaucoma.
US7964728B2 (en) * 2006-07-06 2011-06-21 Solvay Pharmaceuticals B.V. Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
IL266563B (en) * 2009-10-06 2022-09-01 Millennium Pharm Inc Heterocyclic compounds useful as pdk1 inhibitors
EP2771341A4 (en) * 2011-10-28 2015-09-23 Univ Texas NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
KR20230066311A (ko) * 2020-06-10 2023-05-15 델릭스 테라퓨틱스, 인크. 삼환형 사이코플라스토겐 및 이의 용도
EP4255422A4 (en) * 2020-12-03 2024-12-18 Mydecine Innovations Group Inc. NEW PSILOCIN ANALOGUE COMPOSITIONS AND METHODS OF THEIR SYNTHESIS
KR20240058859A (ko) 2021-08-12 2024-05-03 쿨레온 엘엘씨 환각성 및 비환각성 세로토닌 수용체 작용제 및 이의 제조 및 사용 방법

Also Published As

Publication number Publication date
MX2024007911A (es) 2024-09-10
CA3241845A1 (en) 2023-06-29
EP4452979A1 (en) 2024-10-30
CN118974044A (zh) 2024-11-15
US20250163044A1 (en) 2025-05-22
WO2023115165A1 (en) 2023-06-29
EP4452979A4 (en) 2025-11-26
JP2025501141A (ja) 2025-01-17
IL313857A (en) 2024-08-01
AU2022422215A1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
KR20240128059A (ko) 화합물
JP7270989B2 (ja) ムスカリン性アセチルコリン受容体m4のアンタゴニスト
US20250101038A1 (en) Compounds
EP4037677B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP2019023225A (ja) ヘテロアリール化合物及びその使用方法
US20250361233A1 (en) Compounds For Activating Serotonin Receptor
KR20250019650A (ko) 화합물
US12428380B2 (en) Compounds
KR20260053282A (ko) 정신 질환의 치료를 위한 피롤로피리딘 화합물
WO2025118034A1 (en) Compounds active at the serotonergic 5-ht2a receptor
KR20260053507A (ko) 화합물
AU2023342126A1 (en) Negative allosteric modulators of metabotropic glutamate receptor 2

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000